193 related articles for article (PubMed ID: 19778610)
1. Aromatase resistance mechanisms in model systems in vivo.
Brodie A; Macedo L; Sabnis G
J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):283-7. PubMed ID: 19778610
[TBL] [Abstract][Full Text] [Related]
2. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors and xenograft studies.
Chumsri S; Sabnis GJ; Howes T; Brodie AM
Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
[TBL] [Abstract][Full Text] [Related]
5. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
6. Stopping treatment can reverse acquired resistance to letrozole.
Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
[TBL] [Abstract][Full Text] [Related]
7. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
Macedo LF; Sabnis G; Brodie A
Cancer; 2008 Feb; 112(3 Suppl):679-688. PubMed ID: 18072255
[TBL] [Abstract][Full Text] [Related]
8. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
[TBL] [Abstract][Full Text] [Related]
9. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
10. Xenograft models for aromatase inhibitor studies.
Brodie A; Sabnis G; Macedo L
J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and breast cancer.
Macedo LF; Sabnis G; Brodie A
Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202
[TBL] [Abstract][Full Text] [Related]
14. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
15. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
16. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Brodie AH; Jelovac D; Long B
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
18. New approaches to the understanding of tamoxifen action and resistance.
Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic observations in MCF-7 aromatase xenografts.
Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
[TBL] [Abstract][Full Text] [Related]
20. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]